Liberant Thrombectomy System

K250787 · Medtronic, Ireland · QEW · Jun 11, 2025 · Cardiovascular

Device Facts

• Record ID: K250787
• Device Name: Liberant Thrombectomy System
• Applicant: Medtronic, Ireland
• Product Code: QEW · Cardiovascular
• Decision Date: Jun 11, 2025
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 870.5150
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The Liberant Thrombectomy System is indicated for the removal of fresh, soft emboli or thrombi from the vessels of the peripheral arterial and venous systems.

Device Story

Liberant Thrombectomy System performs mechanical aspiration of thrombi from peripheral vasculature. System components include aspiration catheter, clot-buster, dilator, aspiration tubing, hemostasis valve, blood conservation unit (BCU), aspiration pump, and collection canister. Physician inserts catheter over 0.035" guidewire to target occlusion site; pump provides vacuum source for continuous aspiration. Clot-buster tool inserted into catheter lumen to disrupt blockages or assist thrombus removal. Used in clinical settings by physicians. Output is aspirated thrombus material collected in canister. System benefits patient by restoring blood flow in peripheral vessels.

Clinical Evidence

Bench testing included dimensional/visual inspection, simulated use, tensile testing, coating integrity, vacuum testing, and flow/blockage detection. Biocompatibility testing performed per ISO 10993-1 (cytotoxicity, irritation, sensitization, systemic toxicity, haemocompatibility). GLP animal study conducted. Software validation and EMC testing performed. All results met pre-determined acceptance criteria.

Technological Characteristics

System comprises aspiration catheter, clot-buster, BCU, and pump. Catheter sizes: 6F, 8F, 12F. Guidewire compatibility: 0.035". Sterilization: Ethylene Oxide (EO) for single-use set. Biocompatibility per ISO 10993-1. Connectivity: Pump-based vacuum system. Software included for pump control/monitoring.

Indications for Use

Indicated for removal of fresh, soft emboli or thrombi from peripheral arterial and venous vessels in patients requiring mechanical thrombectomy.

Regulatory Classification

Identification

An embolectomy catheter is a balloon-tipped catheter that is used to remove thromboemboli, i.e., blood clots which have migrated in blood vessels from one site in the vascular tree to another.

Predicate Devices

• Indigo Aspiration System (K142870, K192981, K193244)

Submission Summary (Full Text)

{0}

FDA U.S. FOOD & DRUG ADMINISTRATION

June 11, 2025

Medtronic, Ireland
Barbara Zampedri
Sr Regulatory Affairs Specialist
Parkmore Business Park West
Galway, Ireland

Re: K250787
Trade/Device Name: Liberant Thrombectomy System
Regulation Number: 21 CFR 870.5150
Regulation Name: Embolectomy Catheter
Regulatory Class: Class II
Product Code: QEW
Dated: March 14, 2025
Received: March 14, 2025

Dear Barbara Zampedri:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device"

U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov

{1}

K250787 - Barbara Zampedri
Page 2

(https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

{2}

K250787 - Barbara Zampedri
Page 3

Sincerely,

Digitally signed by ARIEL G. ASH-SHAKOOR -S
Date: 2025.06.11 09:39:35 -04'00"

For
Gregory O'Connell
Assistant Director
DHT2C: Division of Coronary and Peripheral Intervention Devices
OHT2: Office of Cardiovascular Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

{3}

FORM FDA 3881 (8/23)
Page 1 of 1
PSC Publishing Services [phone]
EF

| DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Indications for Use | Form Approved: OMB No. 0910-0120 Expiration Date: 07/31/2026 See PRA Statement below. |
| --- | --- |
| 510(k) Number (if known) K250787 | |
| Device Name Liberant Thrombectomy System | |
| Indications for Use (Describe) The Liberant Thrombectomy System is indicated for the removal of fresh, soft emboli or thrombi from the vessels of the peripheral arterial and venous systems. | |
| Type of Use (Select one or both, as applicable) ☑ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C) | |
| CONTINUE ON A SEPARATE PAGE IF NEEDED. | |
| This section applies only to requirements of the Paperwork Reduction Act of 1995. *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* | |
| The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail] | |
| "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." | |

{4}

K250787

# 510(k) Summary

This summary of 510(k) substantial equivalence information is being submitted in accordance with the requirements of 21 CFR 807.92.

## Submitter Information

| Applicant/ Submitter Name and Address | Medtronic Ireland
Parkmore Business Park West
Galway, Ireland |
| --- | --- |
| Contact Person | Barbara Zampedri
Senior Regulatory Affairs Specialist
Email: [e-mail] |
| Date Prepared | June 06, 2025 |
| Device Trade Name | Liberant™ Thrombectomy System |

## Subject Device

| Device Classification | Regulatory Class: II |
| --- | --- |
| Classification Panel | Cardiovascular
Coronary and Peripheral Interventional Devices |
| Classification Name | Peripheral Mechanical Thrombectomy with Aspiration |
| Regulation Number | 21 CFR 870.5150 |
| Product Code | QEW |

## Predicate Device

| Device Trade name | Indigo Aspiration System |
| --- | --- |
| 510(K) Number / Clearance Date | K142870 / May 26, 2015
K192981 / May 28, 2020
K193244 / March 13, 2020 |

## Device Description

The Liberant Thrombectomy System consists of the Liberant Thrombectomy Set (catheter, clot-buster, dilator, aspiration tubing and hemostasis valve), Liberant Blood Conservation Unit (BCU), Riptide Aspiration Pump and Riptide Collection Canister with intermediate tubing. The Liberant Thrombectomy Set is single use and provided sterile.

The Liberant BCU and Riptide Pump are provided separately from the Liberant Thrombectomy Set as non-sterile capital units. The single use, non-sterile Riptide Collection Canister is provided separately to the pump.

{5}

K250787

# Indications for Use

The Liberant Thrombectomy System is indicated for the removal of fresh, soft emboli or thrombi from the vessels of the peripheral arterial and venous systems.

## Predicate Comparison

| Attribute | Predicate Device | Subject Device |
| --- | --- | --- |
| Trade Name | Penumbra INDIGO Aspiration System | Liberant Thrombectomy System |
| 510(k) Number | K142870, K192981, K193244 | K250787 |
| Classification | Class II, QEW | Same |
| Regulation Number | 870.5150 – Embolectomy Catheter | Same |
| Indications For Use | INDIGO Aspiration Catheters and Separators:
As part of the INDIGO Aspiration System, the INDIGO Aspiration Catheters and Separators are indicated for the removal of fresh, soft emboli and thrombi from vessels of the peripheral arterial and venous systems.

INDIGO Aspiration Tubing:
As part of the INDIGO Aspiration System, the INDIGO Sterile Aspiration Tubing is indicated to connect the INDIGO Aspiration Catheters to the Penumbra Aspiration Pump. | The Liberant Thrombectomy System is indicated for the removal of fresh, soft emboli or thrombi from the vessels of the peripheral arterial and venous systems. |

{6}

K250787
| Attribute | Predicate Device | Subject Device |
| --- | --- | --- |
| Trade Name | Penumbra INDIGO Aspiration System | Liberant Thrombectomy System |
| Basic Operating Principle/ General Technological Design | Continuous aspiration: Continuous aspiration and removal of emboli and thrombus via a vacuum aspiration source with the catheter targeted at thrombus in the peripheral vasculature.

Access: The aspiration catheter accesses the thrombotic occlusions within the vasculature and is used to aspirate material directly through the catheter lumen. The catheter is introduced over a guidewire (0.035”) to the site of the target occlusion to perform aspiration when connected to the aspiration pump that serves as a vacuum source.

Fragmentation Tool: A separator, supplied separately, may be used to assist with thrombus removal and to clear the lumen of the catheter should it become blocked. In the event of catheter blockages, the separator can be inserted into the catheter lumen to disrupt the blockage. | Continuous aspiration: Same

Access: Same

Fragmentation Tool: A clotbuster, supplied with the catheter, may be used to assist with thrombus removal and to clear the lumen of the catheter should it become blocked. In the event of catheter blockages, the clotbuster can be inserted into the catheter lumen to disrupt the blockage. |
| **Aspiration Catheter** | | |
| Sizes Available | 6F
8F
12F | 6F
8F
12F |
| Catheter Effective Lengths | 6F: 135 cm
8F Short: 50cm
8F Long: 115cm
12F: 115cm | Same |
| Guidewire Compatibility | 0.035” | Same |
| **Clotbuster** | | |
| Length | SEP6: 175cm
SEP D: 90cm
SEP8: 150cm
SEP12: 150cm | 6F: 151cm
8F Short: 66cm
8F Long: 131cm
12F: 131cm |
| **General** | | |
| Biocompatibility | Per ISO 10993-1 | Same |
| Sterilization | Ethylene Oxide (EO) | Thrombectomy Set: Same
BCU: non-sterile |
| Shelf Life | 36 months | Thrombectomy Set: 6 months
BCU operational lifetime: 500 hours |

{7}

K250787

# Summary of Non-Clinical Data

Medtronic performed design verification and validation testing to provide evidence to demonstrate substantial equivalence of the subject device to the predicate device. All data met the acceptance criteria and fell within pre-determined product specifications. The follow testing was performed:

## Performance Testing:

- Dimensional/Visual Inspection
- Performance/Simulated Use Testing
- Tensile Testing
- Coating Integrity
- Aspiration Tubing compatibility
- Vacuum Testing
- Blockage & Flow detection
- Direct User Testing
- Human Factors & Usability Testing
- GLP animal study

## Biocompatibility Evaluation:

- Cytotoxicity Colony Assay
- Systemic Toxicity Material Mediated Rabbit Pyrogen
- ISO Intracutaneous Irritation test
- In Vitro Skin Irritation Assay
- ISO Acute Systemic Toxicity Study
- ISO Maximisation Sensitisation in Guinea Pigs
- Haemocompatibility

Shelf-life

Sterilization

Packaging

Software Validation

Electrical and Electromagnetic compatibility testing

# Conclusion

Non-clinical testing supports substantial equivalence of the subject device, Liberant Thrombectomy System, to the predicate device, Penumbra Indigo Aspiration System.